---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-024057"
form_type: "8-K"
ticker: null
cik: "0001492674"
company_name: "T2 Biosystems, Inc."
filed_at: "2025-02-11T23:59:59+00:00"
generated_at: "2026-05-26T23:19:56.208676+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# T2 Biosystems receives Nasdaq delisting; stock to trade OTC from Feb 12

## Summary
- Nasdaq Panel determined to delist T2 Biosystems common stock; trading suspended at open on Feb 12, 2025.
- Company violated Bid Price Rule (5550(a)(2)) and Market Value of Listed Securities Rule (5550(b)(2)).
- Company will not appeal; expects Nasdaq to file Form 25-NSE with SEC.
- Stock to trade under TTOO on OTC Markets starting Feb 12; plans to apply for OTCQX quotation.
- No assurance of continued trading liquidity or broker-dealer support on OTC market.

## SEC filing metadata
- accession: 0001193125-25-024057
- form_type: 8-K
- cik: 0001492674
- company_name: T2 Biosystems, Inc.
- filed_at: 2025-02-11T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492674/000119312525024057/0001193125-25-024057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492674/000119312525024057/d869925d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-024057
- JSON: https://secwatch.observer/filing/0001193125-25-024057.json
- Plain text: https://secwatch.observer/filing/0001193125-25-024057.txt

## Key facts
- Listing & Compliance Notices
  T2 Biosystems, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5550(b)(2)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5550(b)(2)
  source text: February 10, 2025, the Nasdaq Stock Market LLC (“Nasdaq”) notified T2 Biosystems, Inc. (the “Company”) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s common stock and that trading of the Company’s common stock will be suspended at the open of trading on February 12, 2025. As previously reported, the Company was in violation of the bid price requirement of Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) and the market value of listed securities requirement in Listing Rule 5550(b)(2) (the “MVLS Rule”). In accordance with the terms of the previously impo
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492674/000119312525024057/0001193125-25-024057-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.